Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 1494 818 026 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
+44 1494 818 026

Things took another turn as the client then contacted me direct after talks had already begun with you - and I immediately informed you of the situation.
Farah, 2012

Bristol-Myers Squibb reports trial data for new Orencia formulation

9 November 2010 00:00 in Pharmaceutical Company Product News

Bristol-Myers Squibb has published new clinical study data which illustrates the potential benefits of a new formulation of its drug Orencia.

The company has conducted a phase III trial to evaluate the efficacy of a weekly subcutaneous administration of the rheumatoid arthritis treatment, following a single intravenous (IV) loading dose.

It was found that the investigational formulation was able to deliver a similar improvement in disease activity to the currently approved monthly IV dosage method.

The results mean the therapy was able to meet its primary efficacy endpoint in the Acquire clinical study, which was conducted among 1,457 patients over six months.

Dr Mark Genovese, professor of medicine at Stanford University Medical Center, said: "These findings are significant because they demonstrate that subcutaneous Orencia may provide an additional administration option for patients and physicians."

Earlier this month, Bristol-Myers Squibb agreed a new collaboration with Simcere Pharmaceutical Group, a China-based company, to jointly develop a new cancer treatment.ADNFCR-8000103-ID-800224531-ADNFCR

Other news stories from 09/11/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd